Comparative Pharmacology
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOCLEAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUAPHYLLIN versus THEOCLEAR 80.
AQUAPHYLLIN vs THEOCLEAR-80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular cAMP and cGMP, leading to bronchodilation and anti-inflammatory effects.
Inhibits phosphodiesterase, increasing cAMP levels, leading to bronchodilation and reduced airway inflammation.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
Oral: 400-800 mg every 6-8 hours; extended-release formulation given every 12 hours. Target serum concentration 10-20 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
3–8 hours in adults (mean ~5 h); prolonged in heart failure, liver disease, and COPD; decreased in smokers (4–5 h) and children.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of elimination; metabolites excreted in urine.
Category C
Category C
Bronchodilator
Bronchodilator